IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between March 10, 2021 and December 15, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 4, 2024.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Checkpoint failed to maintain appropriate controls over third-party manufacturers. The Company suffered from multiple issues with its third-party contract manufacturers for cosibelimab. These problems would impact the likelihood of cosibelimab achieving FDA approval. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Checkpoint, investors suffered damages.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.